Calcimedica announces presentations at upcoming medical meetings

La jolla, calif. , april 17, 2025 /prnewswire/ -- calcimedica inc. ("calcimedica" or the "company") (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (crac) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the acceptance of an abstract for poster presentation at digestive disease week (ddw) 2025 being held may 3-6 in san diego, ca, and the participation of sudarshan hebbar, m.d.
CALC Ratings Summary
CALC Quant Ranking